 | • レポートコード：GIR-2104Z06896 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、遺伝性血管浮腫治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。遺伝性血管浮腫治療の種類別市場規模（C1エステラーゼ阻害剤（血漿製品、組換え製品）、選択的ブラジキニンB2受容体拮抗薬、カリクレイン阻害剤、その他（従来薬、パイプライン薬））、用途別市場規模（病院薬局、小売薬局、その他（オンライン薬局、郵便薬局））、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・遺伝性血管浮腫治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：CSL、Pharming Group、Shire plc (Takeda Pharmaceutical Company Limited)、Ionis Pharmaceuticals、Attune Pharmaceuticals、BioCryst Pharmaceuticals、KalVista Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：C1エステラーゼ阻害剤（血漿製品、組換え製品）、選択的ブラジキニンB2受容体拮抗薬、カリクレイン阻害剤、その他（従来薬、パイプライン薬） ・用途別分析2016年-2026年：病院薬局、小売薬局、その他（オンライン薬局、郵便薬局） ・遺伝性血管浮腫治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・遺伝性血管浮腫治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・遺伝性血管浮腫治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・遺伝性血管浮腫治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・遺伝性血管浮腫治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Hereditary Angioedema Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Hereditary Angioedema Treatment size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Hereditary Angioedema Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Hereditary Angioedema Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
Selective Bradykinin B2 Receptor Antagonists (Firazyr)
Kallikrein Inhibitors (Kalbitor, Takhzyro)
Others (Conventional Drugs, Pipeline Drugs)
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Others (online pharmacies, mail pharmacies)
The key market players for global Hereditary Angioedema Treatment market are listed below:
CSL
Pharming Group
Shire plc (Takeda Pharmaceutical Company Limited)
Ionis Pharmaceuticals
Attune Pharmaceuticals
BioCryst Pharmaceuticals
KalVista Pharmaceuticals
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Hereditary Angioedema Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hereditary Angioedema Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
1.2.3 Selective Bradykinin B2 Receptor Antagonists (Firazyr)
1.2.4 Kallikrein Inhibitors (Kalbitor, Takhzyro)
1.2.5 Others (Conventional Drugs, Pipeline Drugs)
1.3 Market Analysis by Application
1.3.1 Overview: Global Hereditary Angioedema Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Others (online pharmacies, mail pharmacies)
1.4 Global Hereditary Angioedema Treatment Market Size & Forecast
1.4.1 Global Hereditary Angioedema Treatment Sales in Value (2016-2026))
1.4.2 Global Hereditary Angioedema Treatment Sales in Volume (2016-2026)
1.4.3 Global Hereditary Angioedema Treatment Price by Type (2016-2026) & (USD/Unit)
1.5 Global Hereditary Angioedema Treatment Production Capacity Analysis
1.5.1 Global Hereditary Angioedema Treatment Total Production Capacity (2016-2026)
1.5.2 Global Hereditary Angioedema Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hereditary Angioedema Treatment Market Drivers
1.6.2 Hereditary Angioedema Treatment Market Restraints
1.6.3 Hereditary Angioedema Treatment Trends Analysis
2 Manufacturers Profiles
2.1 CSL
2.1.1 CSL Details
2.1.2 CSL Major Business
2.1.3 CSL Hereditary Angioedema Treatment Product and Services
2.1.4 CSL Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Pharming Group
2.2.1 Pharming Group Details
2.2.2 Pharming Group Major Business
2.2.3 Pharming Group Hereditary Angioedema Treatment Product and Services
2.2.4 Pharming Group Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Shire plc (Takeda Pharmaceutical Company Limited)
2.3.1 Shire plc (Takeda Pharmaceutical Company Limited) Details
2.3.2 Shire plc (Takeda Pharmaceutical Company Limited) Major Business
2.3.3 Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Product and Services
2.3.4 Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Ionis Pharmaceuticals
2.4.1 Ionis Pharmaceuticals Details
2.4.2 Ionis Pharmaceuticals Major Business
2.4.3 Ionis Pharmaceuticals Hereditary Angioedema Treatment Product and Services
2.4.4 Ionis Pharmaceuticals Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Attune Pharmaceuticals
2.5.1 Attune Pharmaceuticals Details
2.5.2 Attune Pharmaceuticals Major Business
2.5.3 Attune Pharmaceuticals Hereditary Angioedema Treatment Product and Services
2.5.4 Attune Pharmaceuticals Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 BioCryst Pharmaceuticals
2.6.1 BioCryst Pharmaceuticals Details
2.6.2 BioCryst Pharmaceuticals Major Business
2.6.3 BioCryst Pharmaceuticals Hereditary Angioedema Treatment Product and Services
2.6.4 BioCryst Pharmaceuticals Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 KalVista Pharmaceuticals
2.7.1 KalVista Pharmaceuticals Details
2.7.2 KalVista Pharmaceuticals Major Business
2.7.3 KalVista Pharmaceuticals Hereditary Angioedema Treatment Product and Services
2.7.4 KalVista Pharmaceuticals Hereditary Angioedema Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Hereditary Angioedema Treatment Sales by Manufacturer
3.1 Global Hereditary Angioedema Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Hereditary Angioedema Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Hereditary Angioedema Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Hereditary Angioedema Treatment Manufacturer Market Share
3.4.2 Top 6 Hereditary Angioedema Treatment Manufacturer Market Share
3.5 Global Hereditary Angioedema Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Hereditary Angioedema Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hereditary Angioedema Treatment Market Size by Region
4.1.1 Global Hereditary Angioedema Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Hereditary Angioedema Treatment Revenue by Region (2016-2026)
4.2 North America Hereditary Angioedema Treatment Revenue (2016-2026)
4.3 Europe Hereditary Angioedema Treatment Revenue (2016-2026)
4.4 Asia-Pacific Hereditary Angioedema Treatment Revenue (2016-2026)
4.5 South America Hereditary Angioedema Treatment Revenue (2016-2026)
4.6 Middle East and Africa Hereditary Angioedema Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Hereditary Angioedema Treatment Sales in Volume by Type (2016-2026)
5.2 Global Hereditary Angioedema Treatment Revenue by Type (2016-2026)
5.3 Global Hereditary Angioedema Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Hereditary Angioedema Treatment Sales in Volume by Application (2016-2026)
6.2 Global Hereditary Angioedema Treatment Revenue by Application (2016-2026)
6.3 Global Hereditary Angioedema Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Hereditary Angioedema Treatment Sales by Type (2016-2026)
7.2 North America Hereditary Angioedema Treatment Sales by Application (2016-2026)
7.3 North America Hereditary Angioedema Treatment Market Size by Country
7.3.1 North America Hereditary Angioedema Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Hereditary Angioedema Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Hereditary Angioedema Treatment Sales by Type (2016-2026)
8.2 Europe Hereditary Angioedema Treatment Sales by Application (2016-2026)
8.3 Europe Hereditary Angioedema Treatment Market Size by Country
8.3.1 Europe Hereditary Angioedema Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Hereditary Angioedema Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Hereditary Angioedema Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Hereditary Angioedema Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Hereditary Angioedema Treatment Market Size by Region
9.3.1 Asia-Pacific Hereditary Angioedema Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Hereditary Angioedema Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Hereditary Angioedema Treatment Sales by Type (2016-2026)
10.2 South America Hereditary Angioedema Treatment Sales by Application (2016-2026)
10.3 South America Hereditary Angioedema Treatment Market Size by Country
10.3.1 South America Hereditary Angioedema Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Hereditary Angioedema Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hereditary Angioedema Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Hereditary Angioedema Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Hereditary Angioedema Treatment Market Size by Country
11.3.1 Middle East & Africa Hereditary Angioedema Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Hereditary Angioedema Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Hereditary Angioedema Treatment Typical Distributors
12.3 Hereditary Angioedema Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Hereditary Angioedema Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Hereditary Angioedema Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. CSL Basic Information, Manufacturing Base and Competitors
Table 4. CSL Major Business
Table 5. CSL Hereditary Angioedema Treatment Product and Services
Table 6. CSL Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Pharming Group Basic Information, Manufacturing Base and Competitors
Table 8. Pharming Group Major Business
Table 9. Pharming Group Hereditary Angioedema Treatment Product and Services
Table 10. Pharming Group Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Shire plc (Takeda Pharmaceutical Company Limited) Basic Information, Manufacturing Base and Competitors
Table 12. Shire plc (Takeda Pharmaceutical Company Limited) Major Business
Table 13. Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Product and Services
Table 14. Shire plc (Takeda Pharmaceutical Company Limited) Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Ionis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Ionis Pharmaceuticals Major Business
Table 17. Ionis Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 18. Ionis Pharmaceuticals Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Attune Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. Attune Pharmaceuticals Major Business
Table 21. Attune Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 22. Attune Pharmaceuticals Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. BioCryst Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. BioCryst Pharmaceuticals Major Business
Table 25. BioCryst Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 26. BioCryst Pharmaceuticals Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. KalVista Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. KalVista Pharmaceuticals Major Business
Table 29. KalVista Pharmaceuticals Hereditary Angioedema Treatment Product and Services
Table 30. KalVista Pharmaceuticals Hereditary Angioedema Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Hereditary Angioedema Treatment Sales by Manufacturer (2019-2021e) & (K Units)
Table 32. Global Hereditary Angioedema Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Hereditary Angioedema Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Hereditary Angioedema Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Hereditary Angioedema Treatment Production Site of Key Manufacturer
Table 36. Global Hereditary Angioedema Treatment Sales by Region (2016-2021e) & (K Units)
Table 37. Global Hereditary Angioedema Treatment Sales by Region (2021-2026) & (K Units)
Table 38. Global Hereditary Angioedema Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 39. Global Hereditary Angioedema Treatment Revenue by Region (2021-2026) & (USD Million)
Table 40. Global Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 41. Global Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 42. Global Hereditary Angioedema Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 43. Global Hereditary Angioedema Treatment Revenue by Type (2021-2026) & (USD Million)
Table 44. Global Hereditary Angioedema Treatment Price by Type (2016-2021e) & (USD/Unit)
Table 45. Global Hereditary Angioedema Treatment Price by Type (2021-2026) & (USD/Unit)
Table 46. Global Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 47. Global Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 48. Global Hereditary Angioedema Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 49. Global Hereditary Angioedema Treatment Revenue by Application (2021-2026) & (USD Million)
Table 50. Global Hereditary Angioedema Treatment Price by Application (2016-2021e) & (USD/Unit)
Table 51. Global Hereditary Angioedema Treatment Price by Application (2021-2026) & (USD/Unit)
Table 52. North America Hereditary Angioedema Treatment Sales by Country (2016-2021e) & (K Units)
Table 53. North America Hereditary Angioedema Treatment Sales by Country (2021-2026) & (K Units)
Table 54. North America Hereditary Angioedema Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 55. North America Hereditary Angioedema Treatment Revenue by Country (2021-2026) & (USD Million)
Table 56. North America Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 57. North America Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 58. North America Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 59. North America Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 60. Europe Hereditary Angioedema Treatment Sales by Country (2016-2021e) & (K Units)
Table 61. Europe Hereditary Angioedema Treatment Sales by Country (2021-2026) & (K Units)
Table 62. Europe Hereditary Angioedema Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 63. Europe Hereditary Angioedema Treatment Revenue by Country (2021-2026) & (USD Million)
Table 64. Europe Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 65. Europe Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 66. Europe Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 67. Europe Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 68. Asia-Pacific Hereditary Angioedema Treatment Sales by Region (2016-2021e) & (K Units)
Table 69. Asia-Pacific Hereditary Angioedema Treatment Sales by Region (2021-2026) & (K Units)
Table 70. Asia-Pacific Hereditary Angioedema Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 71. Asia-Pacific Hereditary Angioedema Treatment Revenue by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 73. Asia-Pacific Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 74. Asia-Pacific Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 75. Asia-Pacific Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 76. South America Hereditary Angioedema Treatment Sales by Country (2016-2021e) & (K Units)
Table 77. South America Hereditary Angioedema Treatment Sales by Country (2021-2026) & (K Units)
Table 78. South America Hereditary Angioedema Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 79. South America Hereditary Angioedema Treatment Revenue by Country (2021-2026) & (USD Million)
Table 80. South America Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 81. South America Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 82. South America Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 83. South America Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 84. Middle East & Africa Hereditary Angioedema Treatment Sales by Country (2016-2021e) & (K Units)
Table 85. Middle East & Africa Hereditary Angioedema Treatment Sales by Country (2021-2026) & (K Units)
Table 86. Middle East & Africa Hereditary Angioedema Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 87. Middle East & Africa Hereditary Angioedema Treatment Revenue by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Hereditary Angioedema Treatment Sales by Type (2016-2021e) & (K Units)
Table 89. Middle East & Africa Hereditary Angioedema Treatment Sales by Type (2021-2026) & (K Units)
Table 90. Middle East & Africa Hereditary Angioedema Treatment Sales by Application (2016-2021e) & (K Units)
Table 91. Middle East & Africa Hereditary Angioedema Treatment Sales by Application (2021-2026) & (K Units)
Table 92. Direct Channel Pros & Cons
Table 93. Indirect Channel Pros & Cons
Table 94. Hereditary Angioedema Treatment Typical Distributors
Table 95. Hereditary Angioedema Treatment Typical Customers
List of Figures
Figure 1. Hereditary Angioedema Treatment Picture
Figure 2. Global Hereditary Angioedema Treatment Sales Market Share by Type in 2020
Figure 3. C1 Estearse Inhibitors (Plasma Products, Recombinant Products)
Figure 4. Selective Bradykinin B2 Receptor Antagonists (Firazyr)
Figure 5. Kallikrein Inhibitors (Kalbitor, Takhzyro)
Figure 6. Others (Conventional Drugs, Pipeline Drugs)
Figure 7. Global Hereditary Angioedema Treatment Sales Market Share by Application in 2020
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Others (online pharmacies, mail pharmacies)
Figure 11. Global Hereditary Angioedema Treatment Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global Hereditary Angioedema Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. United States Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Canada Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Mexico Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Germany Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. France Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. United Kingdom Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Russia Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Italy Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. China Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Japan Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Korea Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. India Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Southeast Asia Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Australia Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Brazil Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Egypt Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Saudi Arabia Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. South Africa Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Turkey Hereditary Angioedema Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Global Hereditary Angioedema Treatment Sales (2016-2026) & (K Units)
Figure 33. Global Hereditary Angioedema Treatment Production Capacity (2016-2026) & (K Units)
Figure 34. Global Hereditary Angioedema Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 35. Hereditary Angioedema Treatment Market Drivers
Figure 36. Hereditary Angioedema Treatment Market Restraints
Figure 37. Hereditary Angioedema Treatment Market Trends
Figure 38. Global Hereditary Angioedema Treatment Sales Market Share by Manufacturer in 2020
Figure 39. Global Hereditary Angioedema Treatment Revenue Market Share by Manufacturer in 2020
Figure 40. Hereditary Angioedema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 41. Top 3 Hereditary Angioedema Treatment Manufacturer (Revenue) Market Share in 2020
Figure 42. Top 6 Hereditary Angioedema Treatment Manufacturer (Revenue) Market Share in 2020
Figure 43. Global Hereditary Angioedema Treatment Sales Market Share by Region (2016-2026)
Figure 44. Global Hereditary Angioedema Treatment Revenue Market Share by Region (2016-2026)
Figure 45. North America Hereditary Angioedema Treatment Revenue (2016-2026) & (USD Million)
Figure 46. Europe Hereditary Angioedema Treatment Revenue (2016-2026) & (USD Million)
Figure 47. Asia-Pacific Hereditary Angioedema Treatment Revenue (2016-2026) & (USD Million)
Figure 48. South America Hereditary Angioedema Treatment Revenue (2016-2026) & (USD Million)
Figure 49. Middle East & Africa Hereditary Angioedema Treatment Revenue (2016-2026) & (USD Million)
Figure 50. Global Hereditary Angioedema Treatment Sales Market Share by Type (2016-2026)
Figure 51. Global Hereditary Angioedema Treatment Revenue Market Share by Type (2016-2026)
Figure 52. Global Hereditary Angioedema Treatment Price by Type (2016-2026) & (USD/Unit)
Figure 53. Global Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 54. Global Hereditary Angioedema Treatment Revenue Market Share by Application (2016-2026)
Figure 55. Global Hereditary Angioedema Treatment Price by Application (2016-2026) & (USD/Unit)
Figure 56. North America Hereditary Angioedema Treatment Sales Market Share by Country (2016-2026)
Figure 57. North America Hereditary Angioedema Treatment Revenue Market Share by Country (2016-2026)
Figure 58. North America Hereditary Angioedema Treatment Sales Market Share by Type (2016-2026)
Figure 59. North America Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 60. Europe Hereditary Angioedema Treatment Sales Market Share by Country (2016-2026)
Figure 61. Europe Hereditary Angioedema Treatment Revenue Market Share by Country (2016-2026)
Figure 62. Europe Hereditary Angioedema Treatment Sales Market Share by Type (2016-2026)
Figure 63. Europe Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific Hereditary Angioedema Treatment Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Hereditary Angioedema Treatment Revenue Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Hereditary Angioedema Treatment Sales Market Share by Region (2016-2026)
Figure 67. Asia-Pacific Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America Hereditary Angioedema Treatment Sales Market Share by Country (2016-2026)
Figure 69. South America Hereditary Angioedema Treatment Revenue Market Share by Country (2016-2026)
Figure 70. South America Hereditary Angioedema Treatment Sales Market Share by Type (2016-2026)
Figure 71. South America Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Hereditary Angioedema Treatment Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Hereditary Angioedema Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Hereditary Angioedema Treatment Sales Market Share by Type (2016-2026)
Figure 75. Middle East & Africa Hereditary Angioedema Treatment Sales Market Share by Application (2016-2026)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の遺伝性血管性浮腫薬市場 2021：企業別、地域別、種類・用途別 The Hereditary Angioedema Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…- 世界の遺伝性がん検査市場規模・現状・予測（2021年-2027年） Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation fr…
- 世界の遺伝性がん検査市場規模・現状・予測（2021年-2027年） Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation fr…
- 世界の血漿プロテアーゼC1阻害剤治療市場規模・現状・予測（2021年-2027年） This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising p…
- 世界の腎臓がん治療薬市場規模・現状・予測（2021年-2027年） Kidney Cancer Treatment Drugs are drugs used to cure kidney cancer. Market growth is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rise in incidence of renal cancer due to growing geriatric population and more prominent smoking habits. Market Analysi…